Small molecule · developed by Sunshine Lake Pharma Co.
Mitizodone is studied as an oral tablet formulation (mitizodone phosphate) in major depressive disorder.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04984512 | Phase 2/3 | Depressive Disorder, Major | Recruiting | SBFM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Depressive Disorder, Major
Updated Nov 1, 2026. Something wrong or missing? Report it on the SBFM page.
See SBFM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SBFM catalysts and pipeline →